|Aerie Pharmaceuticals, Inc.|
2030 Main Street
United States - Map
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its product candidates include Rhopressa, which is a once-daily eye drop that reduces intraocular pressure (IOP) in patients with glaucoma or ocular hypertension and is in Phase III registration trials; and Roclatan, a once-daily eye drop to reduce IOP that has completed Phase IIb clinical trial in patients with open-angle glaucoma and ocular hypertension. The company also provides AR-13533, a second-generation ROCK/NET inhibitor that offers additional IOP-lowering effect in patients with glaucoma is in preclinical studies. Aerie Pharmaceuticals, Inc. was founded in 2005 and is based in Irvine, California.
|Aerie Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jul 1, 2015 is 9. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Vicente Anido Jr., Ph.D.,
Chairman and Chief Exec. Officer
|Mr. Thomas A. Mitro ,
Pres and Chief Operating Officer
|Mr. Richard J. Rubino CPA,
Chief Financial Officer and Sec.
|Dr. Casey C. Kopczynski Ph.D. ,
Co-Founder and Chief Scientific Officer
|Mr. Craig R. Skenes ,
VP of Bus. Devel.
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|